AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00169208 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab
Description: 375 mg/m² IV, D1 each cycle during 4 cycles
Study NCT00169208 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine
Description: 40 mg/m²/day IV , D1 each cycle during 4 cycles
Study NCT00169208 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mitoxantrone
Description: 10 mg/m² IV, D2-3-4 each cycle during 4 cycles
Study NCT03006874 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CJ-12420 100mg QD
Description: CJ-12420 100mg tablets will be orally administered, once daily, for up to 8 weeks. For subjects whose erosive esophagitis is not endoscopically healed at Week 4, subjects will receive additional 4 week treatment of CJ-12420 100mg.
Study NCT03979352 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: artificial pancreas
Description: Insulin delivery via a closed loop single-hormone artificial pancreas system.
Study NCT01992497 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Probiotic
Study NCT01992497 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic
Study NCT04325737 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SEP-363856
Description: Dosing of the SEP-363856 group in Cohort 1 will be initiated at 50 mg SEP-363856 as an oral once daily dose for 3 consecutive days, followed by 75 mg SEP-363856 as an oral once daily dose for 4 consecutive days, and followed by 100 mg SEP-363856 as an oral once daily dose for 7 consecutive days. The SEP-363856 group in Cohort 2 will be dosed at 25 mg SEP-363856 as an oral once daily dose for 3 consecutive days, followed by 50 mg SEP-363856 as an oral once daily dose for 3 consecutive days, followed by 75 mg SEP-363856 as an oral once daily dose for 4 consecutive days, and followed by 100 mg SEP-363856 as an oral once daily dose for 7 consecutive days.
Study NCT03006874 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esomeprazole 40mg
Description: Esomeprazole 40mg tablets will be orally administered, once daily, for up to 8 weeks. For subjects whose erosive esophagitis is not endoscopically healed at Week 4, subjects will receive additional 4 week treatment of Esomeprazole 40mg.
Study NCT03006874 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CJ-12420 50mg QD
Description: CJ-12420 50mg tablets will be orally administered, once daily, for up to 8 weeks. For subjects whose erosive esophagitis is not endoscopically healed at Week 4, subjects will receive additional 4 week treatment of CJ-12420 50mg.
Study NCT02098278 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAT-2003
Study NCT02098278 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT01108523 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HP828-101
Study NCT03219346 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: oral care program
Description: Oral care (sputum and special needs of people cleaning teeth) time for three days a week (with swallowing treatment time before), once a day, each about 10 minutes of oral care program.
Study NCT00894946 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lipiodol + IVF
Description: IVF preceded by lipiodol
Study NCT00894946 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: IVF
Description: IVF alone
Study NCT04325737 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be orally administered according to the same administration schedule as the SEP-363856 group in each cohort.
Study NCT03669237 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: different reconstruction methods
Description: Different reconstruction methods should be performed after sphincter preservation surgery in two groups.The methods include end-to-end anastomosis or end-to-side anastomosis
Study NCT02725229 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: parasternal block
Description: parasternal block and PCA for sternotomy pain
Study NCT02725229 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TENS group
Description: TENS and PCA for sternotomy pain
Study NCT03639337 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Multi-strain probiotic
Description: 30 days of administration of multi-strain probiotics containing 3.5 x 109 UFC of Bifidobacterium longum BB536, Bifidobacterium breve M-16V and Bifidobacterium infantis M-63
Study NCT00868933 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low glycemic index dietary intervention program
Description: The intervention group involves dietary advice and monitoring. No drug or invasive procedure is involved.
Study NCT00868933 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: simple lifestyle advice
Description: The control group receives lifestyle advice from a clinician, and the clinical care is not inferior to current practice.
Study NCT03935633 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CN128 Tablets
Description: Iron chelator， oral tablets
Study NCT01108536 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: adaptive prosthetic socket
Description: trans tibial socket with actuator zones (inflatable fluid bladders)
Study NCT03513484 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Given IV or SC
Study NCT03513484 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03513484 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nintedanib
Description: Given PO
Study NCT00132418 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enbrel
Description: Enbrel
Study NCT00132418 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT02725229 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: control group
Description: PCA for sternotomy pain
Study NCT03135938 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Grading Inferior Oblique Anterior Transposition surgery
Description: in the grading group, IO muscle of the eye with more severe DVD will be sutured at the level of IR insertion and IO muscle of the eye with lower magnitude of DVD will be sutured 2mm posterior to the sclera to consider the preoperative DVD difference between the two eyes.
Study NCT03135938 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Classic Inferior Oblique Anterior Transposition surgery
Description: in the classic group, IO muscle will be sutured to the sclera at the level of inferior rectus (IR) insertion at its temporal border, without considering the asymmetric DVD between the two eyes
Study NCT02373644 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HVLA Thrust Manipulation and DN
Description: HVLA thrust manipulation targeting primarily the lumbar articulations and sacroiliac joint. Up to 10 sessions over 6 weeks. At least one session of dry needling to the lumbo-pelvic muscles and peri-articular ligaments of the SI joint.
Study NCT02373644 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Physical Therapy
Description: Therapeutic exercise and manual therapy, up to 10 sessions over 6 weeks. Patients may receive interferential current and moist heat.
Study NCT04591444 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluoride Varnish
Description: Following the manufacturer's recommendations, it was not necessary to moisten or dry the treated surface beforehand or afterwards. The product was dispensed and manipulated for 15 s until a homogeneous mixture was obtained, applied with a micro brush, flowing into interproximal areas, and quickly adhering to the tooth surface in the presence of saliva.
Study NCT04591444 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glass Ionomer Sealant
Description: Following the manufacturer's recommendations, prophylaxis and prior drying of the treated surface was carried out, the product was also dispensed and manipulated for 15 s until a homogeneous mixture was obtained, applied with a micro brush and light-cured for 20 s.
Study NCT04591444 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Group
Description: 4 weeks after the simulation of the treatment application, participants in the placebo group received DH treatment with the product that had the best effect in the first 4 weeks.
Study NCT01999725 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EDP-788
Description: EDP-788 Capsules and matching placebo capsules. EDP-788 Liquid Suspension and matching placebo. All interventions are given as single doses
Study NCT01999725 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo capsules or matching suspension
Study NCT03668093 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ICCM
Description: comprehensive system for caries management
Study NCT03668093 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CAMBRA
Description: Caries risk assessment model
Study NCT01488201 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01488201 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KHK4827
Study NCT00038558 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgrastim SD/01
Study NCT00038558 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adriamycin
Study NCT00038558 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bleomycin
Study NCT00038558 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinblastine
Study NCT00038558 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DTIC
Study NCT00820716 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise training
Description: Comparison of two methods of exercise training: alternate load versus constant load realized at moderate or high intensities
Study NCT00820716 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise training
Description: Comparison of two methods of exercise training: alternate load versus constant load realized at moderate or high intensities
Study NCT00815893 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexmedetomidine
Description: dexmedetomidine 1.0 mcg/kg infusion for 10minutes
Study NCT00815893 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline 0.9%
Description: 0.9% Normal Saline 0.25ml/kg infusion for 10minues
Study NCT00952146 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transgastric peritoneoscopy (NOTES)
Description: Under general anesthesia an endoscope will be passed through the gastric wall into the peritoneal cavity to examine the peritoneal cavity. At the withdrawal of the endoscope, the gastric access in the stomach wall will be closed with T-tags.
Study NCT00815893 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol 1%
Description: Propofol: The initial target = 3 μg/ml. The TCI is adjusted by 0.5μg/ml according to patient comfort during the procedure.~The Orchestra® Base Primea(Fresenius, Brezins, France) offers a Target Controlled Infusion (TCI) target controlled infusion.
Study NCT02038075 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Cognitive Behavioral Therapy (BCBT)
Study NCT02038075 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment As Usual (TAU)
Study NCT03565614 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reablement
Description: Intensive home-based rehabilitation is delivered up to 3 months by an interprofessional team (nurse, enrolled nurse, physiotherapist, occupational therapist, social worker). The entire team completed a 5-week college course. The team negotiates goal-directed contents of the rehabilitation initiatives with the user. Each user is handled deliberately based on decisions in the team in cooperation with the care managers overarching goals in admitted services. All participants have personal contact persons, and these contact persons have twice the time per participant as compared to traditional home care. The interprofessional team also has regular meetings to discuss every participant, and all rehabilitation goals activities related to those are documented.
Study NCT03565614 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Traditional home care
Description: Traditional home care and required rehabilitation efforts as by the municipality's current practice. Includes the same professions as is included in the reablement intervention, but the team has had no joint college course, does not use the systematic goal-directed and negotiated approach as the reablement intervention, and has about half the time per participant as compared to the reablement intervention.
Study NCT04186871 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: branebrutinib
Description: Specified dose on specified days
Study NCT04186871 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: abatacept
Description: Specified dose on specified days
Study NCT04186871 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: abatacept
Description: Specified dose on specified days
Study NCT04186871 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: branebrutinib placebo
Description: Specified dose on specified days
Study NCT04558021 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niclosamide suspension
Description: 200mg/10ml
Study NCT00713895 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Expert System
Description: an expert system intervention provided the Pathway-To-Change self-help manual and a series of 3 individualized feedback reports at baseline, 3, and 6 months.
Study NCT00713895 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Self-Help
Description: standard smoking cessation self-help manual
Study NCT03145948 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-553
Description: It is administered orally.
Study NCT03145948 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: It is administered orally.
Study NCT02071069 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: 400mg/m2 d1,250mg/m2 every week or 500mg/m2 every 2 weeks
Study NCT02071069 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan
Description: 180 mg/m2 IV every 2 weeks
Study NCT02071069 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: 400mg/m2 on day 1 and 2400mg/m2 civ46h every 2 weeks
Study NCT02969460 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neurotrack Virtual Cognitive Health Program
Study NCT03970291 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PMD-200
Description: The PMD-200 system is comprised of a console and designated finger probe with 4 sensors. The Sensors are Photoplethysmography (PPG) Galvanic Skin Response (GSR), Accelerometer (ACC) and Thermistor (TMP)
Study NCT02557828 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: arterial line placement
Description: radial arterial cannulation placed via palpation or ultrasound technique
Study NCT03083613 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltitrexed
Description: Raltitrexed:3mg/m2,iv,d1, Every 3 weeks
Study NCT03083613 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel:80mg/m2,iv,d1,d8, Every 3 weeks
Study NCT03765554 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06700841 Immediate release tablets
Description: Small molecule tablets in immediate release form
Study NCT03765554 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06700841 Modified release tablets
Description: Small molecule tablets in modified release form
Study NCT02486380 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Toffee full face mask/toffee nasal mask
Description: Toffee full face mask/toffee nasal mask
Study NCT02122536 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Xeomin to right side of face in half of the subjects; Xeomin to left side of face in the other half of subjects
Description: Subjects were randomized to which side of the face would be treated with Xeomin.
Study NCT02122536 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botox to right side of face in half of the subjects (randomized); Botox to the left side of the face in the other half of subjects
Description: Subjects were randomized to which side of the upper face would be treated with Botox
Study NCT01212718 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FUFA
Description: 2600/500 mg/m2 i.v. 24 h via port, 1 time weekly for six weeks, than have a break for 2 weeks (=8 weeks for 1 cycle)
Study NCT01212718 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: systemic chemotherapy
Description: CPT-11, 80 mg/m2 for 90 minutes and 5 FU/FA 2000/500 mg/m2 iv. 24h via port; 1 time weekly for six weeks, than have a break for 2 weeks
Study NCT01941472 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: fluid challenge
Description: A bag of 500ml of normal saline or 4% gelatin (Gelofusine, B. Braun Medical (Suzhou) Company Limited, Suzhou, China) is infused within 15 minutes using a bag pressurized to 300 mmHg. All other treatments, including maintenance fluids, dose of vasoactive agents and ventilator settings, remain unchanged during the study period.
Study NCT04390620 — intervention group
Intervention type: DEVICE
Intervention: Mucosal Closure
Description: mucosal closure in oral surgery (mucosal sutures)
Study NCT01619176 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methotrexate
Description: methotrexate: 7.5mg/week to 15mg/week for 3 months
Study NCT01619176 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: non-steroidal anti-inflammatory drug (NSAID)
Description: NSAID: 100mg twice a day for 3 months
Study NCT01619176 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: leflunomide
Description: leflunomide: 20mg/day for 3 months
Study NCT01619176 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: methotrexate: 7.5mg/week to 15mg/week for 3 months
Study NCT01167231 — intervention group
Intervention type: DRUG
Intervention: Acarbose (Glucobay, BAYG5421)
Description: Patients treated with acarbose tablets under the real-life setting. Dosing regimen customised to the needs of each participating patient according to the investigators assessment
Study NCT03792672 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-653
Description: TAK-653 tablets.
Study NCT01619176 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: non-steroidal anti-inflammatory drug (NSAID)
Description: NSAID: 100mg twice a day for 3 months
Study NCT01619176 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leflunomide
Description: leflunomide: 20mg/day for 3 months
Study NCT01996085 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lisinopril
Description: Angiotensin converting enzyme inhibitor recommended in case of:~1. hyperconstrictive profile (SVRI > 2500-2800 dyn•s•cm-5•m2)~2. hyperdynamic profile (CI > 4.2 l/min/m2 and/or HR > 80/min) and office SBP ≥ 160 mm Hg and/or DBP ≥ 100 mmHg and/or 24-h mean SBP ≥ 140 mm Hg and/or 24-h mean DBP ≥ 90 mm Hg (in combination with nebivolol)~3. hypervolemic profile (man - TFC > 34 1/kOhm; women - TFC > 24 1/kOhm) and office SBP ≥ 160 mm Hg and/or DBP ≥ 100 mmHg and/or 24-h mean SBP ≥ 140 mm Hg and/or 24-h mean DBP ≥ 90 mm Hg (in combination with diuretic)~4. balanced profile
Study NCT01996085 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan
Description: Angiotensin receptor blocker recommended in terms as for lisinopril in case of its intolerance (e.i. cough)
Study NCT01996085 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nebivolol
Description: Beta-blocker recommended in case of:~1.hyperdynamic profile (CI > 4.2 l/min/m2 and/or HR > 80/min)
Study NCT01996085 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indapamide/hydrochlorothiazide
Description: 1. hypervolemic profile (man - TFC > 34 1/kOhm; women - TFC > 24 1/kOhm)~2. hyperconstrictive profile (SVRI > 2500-2800 dyn•s•cm-5•m2) and office SBP ≥ 160 mm Hg and/or DBP ≥ 100 mmHg and or 24-h mean SBP ≥ 140 mm Hg and/or 24-h mean DBP ≥ 90 mm Hg (in combination with lisinopril/telmisartan)
Study NCT01996085 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine
Description: 1/ SVRI > 2800 dyn•s•cm-5•m2 (in combination with lisinopril/telmisartan)
Study NCT01996085 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lisinopril
Description: Drug choice at the discretion of physician (blinded to ICG)
Study NCT01996085 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Telmisartan
Description: Angiotensin receptor blocker recommended as for lisinopril in case of its intolerance (e.i. cough)
Study NCT01996085 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nebivolol
Description: Drug choice at the discretion of physician (blinded to ICG)
Study NCT01996085 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Indapamide/hydrochlorothiazide
Description: Drug choice at the discretion of physician (blinded to ICG)
Study NCT01996085 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine
Description: Drug choice at the discretion of physician (blinded to ICG)